• By ICR Secretariat
• Posted Monday, June 26, 2023

Eli Lilly's Mounjaro is primed to overtake Novo Nordisk's popular diabetes and obesity duo: report

https://www.fiercepharma.com/pharma/lilly-primed-surpass-novo-nordisk-semaglutide-sales-globaldata

In the battle for superiority in the field of next-gen diabetes and obesity treatments, Novo Nordisk holds the lead as the developer of the metabolism-regulating treatment semaglutide.